Diabetes device maker (insulin pumps, sensors) spun off from Medtronic in 2026, continuing the legacy MiniMed diabetes business.
Diabetes device maker (insulin pumps, sensors) spun off from Medtronic in 2026, continuing the legacy MiniMed diabetes business.
Sells insulin pump systems and the consumables patients must reorder, such as infusion sets and sensors, so each pump placed brings repeat income for years of use; insurers pay for most of it. It operates standalone after separating from Medtronic.
Moat: narrow (installed base, switching costs, brand). Long-standing MiniMed brand and installed pump base, though newly independent after decades inside Medtronic.
Headquarters: Northridge, California, USA · Founded: 1983 · Employees: 8,000
Size MiniMed (MMED) is a United States Health Care company (Medical Specialties) with a market value of $4.78B, the 1208th largest of 3,085 United States companies the cockpit tracks. Shares closed at $16.99 on 18 Nov 2026.
Performance Over six months the shares gained 46.1%, against +23.4% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 14.2% over the last twelve months (peer median +7.0%); the operating margin is 13.9% (peer median 13.6%).
Valuation It trades at 26.3× forward earnings against a peer median of 20.4× (5th most expensive of 20).
Capital Return on invested capital runs 3.3 points above its cost of capital (6.6% WACC).
Backlog Backlog (remaining performance obligations) was $23.0M at 23 Jan 2026. Backlog detail →
Short interest Short interest is 3.5% of the free float (30 Oct 2026).
Next results Next results expected around 30 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $3.10B | $2.71B |
| Revenue growth | — | +14% | — |
| Gross profit | n/a | $1.80B | $1.56B |
| EBITDA | n/a | $587M | $486M |
| Net income | n/a | -$333M | -$213M |
| Free cash flow | n/a | -$420M | -$53.0M |
| Capital expenditure | n/a | $223M | $193M |
| Total debt | $59.0M | $53.0M | $67.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| MiniMed MMED | $4.78B | +46% | +14% | 14% | 26.3× | n/a |
| Insulet PODD | $9.71B | -11% | +26% | 18% | 18.6× | 10.6% |
| Tandem Diabetes Care TNDM | $1.19B | +13% | +7% | -2% | n/a | n/a |
| Dexcom DXCM | $30.8B | +16% | +13% | 24% | 28.0× | 19.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MMED | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.9% | +5.5% | 8th lowest of 21 |
| 6-month return | +46.1% | +23.4% | 5th highest of 21 |
| Distance from 52-week high | -30.4% | -16.4% | 5th lowest of 21 |
| Revenue growth (TTM) | +14.2% | +7.0% | 6th highest of 21 |
| Operating margin | 13.9% | 13.6% | 10th highest of 20 |
| Forward P/E | 26.3× | 20.4× | 5th most expensive of 20 |
| ROIC minus cost of capital | +3.3 pp | +2.0 pp | 8th highest of 20 |
| EV / EBITDA | 7.9× | 13.8× | 3rd cheapest of 14 |
| Net debt / EBITDA | -0.2× | 0.9× | 4th least indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| MiniMed MMED | United States | $4.78B | +46% | +14% | 14% | 26.3× | n/a | n/a |
| DiaSorin DIA.MI | Italy | $4.81B | +24% | -3% | 24% | 20.5× | 4.1% | +6.3% |
| Intco Medical Technology 300677.SZ | China | $4.82B | -2% | +33% | 20% | 18.5× | -3.5% | -6.4% |
| Sotera Health SHC | United States | $4.65B | +5% | +7% | 37% | 15.7× | 14.4% | +7.3% |
| GRAIL GRAL | United States | $4.59B | +67% | +17% | -332% | n/a | n/a | n/a |
| ICU Medical ICUI | United States | $4.46B | +38% | -6% | 8% | 19.4× | 18.9% | +11.9% |
| Merit Medical Systems MMSI | United States | $5.15B | +33% | +9% | 14% | 19.1× | 12.6% | +9.5% |
| LivaNova LIVN | United States | $5.21B | +28% | +12% | 15% | 20.9× | 14.2% | +8.2% |
| Stevanato STVN | United States | $4.19B | -13% | +12% | 18% | 22.5× | 13.1% | +12.1% |
| Jiangsu Yuyue Medical Equipment & Supply 002223.SZ | China | $4.18B | -3% | -1% | 13% | 20.0× | 4.9% | +3.4% |
| Haemonetics HAE | United States | $5.59B | +106% | +4% | 19% | 20.7× | 10.9% | +8.9% |
| Fielmann FIE.DE | Germany | $3.92B | -3% | +3% | 14% | 17.1× | -5.5% | +11.3% |
| CareDx CDNA | United States | $3.91B | +252% | +39% | 1% | 50.6× | n/a | n/a |
| Andon Health 002432.SZ | China | $3.86B | -24% | -30% | -26% | 16.1× | -6.6% | -7.4% |
| Envista NVST | United States | $3.81B | 0% | +10% | 12% | 14.7× | 4.8% | +7.1% |
| APT Medical 688617.SS | China | $6.06B | +23% | +28% | 37% | 38.6× | 9.0% | +40.1% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.73B | +32% | +4% | 15% | 23.0× | 12.7% | +11.0% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -1% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| Tecan TECN.SW | Switzerland | $3.60B | +59% | -4% | 1% | 35.5× | 45.4% | +3.8% |
| Sumitomo Bakelite 4203.T | Japan | $3.50B | +7% | +15% | 13% | 15.9× | 8.6% | +8.9% |
| Ambu A/S AMBU-B.CO | Denmark | $3.47B | +31% | +7% | 13% | 28.8× | 10.0% | +10.0% |
MiniMed reported $23.0M of remaining performance obligations at 23 Jan 2026.